Atria Investments LLC Has $726,000 Holdings in Regeneron Pharmaceuticals Inc (REGN)

Atria Investments LLC boosted its stake in Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 50.4% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,930 shares of the biopharmaceutical company’s stock after buying an additional 647 shares during the period. Atria Investments LLC’s holdings in Regeneron Pharmaceuticals were worth $726,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Thrivent Financial For Lutherans increased its holdings in shares of Regeneron Pharmaceuticals by 2.2% during the second quarter. Thrivent Financial For Lutherans now owns 2,850 shares of the biopharmaceutical company’s stock valued at $1,400,000 after purchasing an additional 60 shares during the period. Mutual of America Capital Management LLC increased its holdings in shares of Regeneron Pharmaceuticals by 1.7% during the second quarter. Mutual of America Capital Management LLC now owns 9,267 shares of the biopharmaceutical company’s stock valued at $4,551,000 after purchasing an additional 153 shares during the period. Quantbot Technologies LP increased its holdings in shares of Regeneron Pharmaceuticals by 253.7% during the second quarter. Quantbot Technologies LP now owns 962 shares of the biopharmaceutical company’s stock valued at $472,000 after purchasing an additional 690 shares during the period. Ark Investment Management LLC increased its holdings in shares of Regeneron Pharmaceuticals by 78.8% during the second quarter. Ark Investment Management LLC now owns 1,234 shares of the biopharmaceutical company’s stock valued at $606,000 after purchasing an additional 544 shares during the period. Finally, Suntrust Banks Inc. increased its holdings in shares of Regeneron Pharmaceuticals by 1.9% during the second quarter. Suntrust Banks Inc. now owns 3,194 shares of the biopharmaceutical company’s stock valued at $1,568,000 after purchasing an additional 59 shares during the period. 66.63% of the stock is currently owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Inc (NASDAQ REGN) opened at $371.53 on Monday. The company has a debt-to-equity ratio of 0.12, a current ratio of 3.63 and a quick ratio of 3.07. Regeneron Pharmaceuticals Inc has a 1 year low of $340.09 and a 1 year high of $543.55. The firm has a market capitalization of $39,920.00, a price-to-earnings ratio of 33.74, a P/E/G ratio of 1.43 and a beta of 1.52.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported $3.99 earnings per share for the quarter, beating the Zacks’ consensus estimate of $3.83 by $0.16. Regeneron Pharmaceuticals had a return on equity of 25.73% and a net margin of 23.17%. The business had revenue of $1.50 billion during the quarter, compared to analyst estimates of $1.45 billion. During the same quarter last year, the company posted $3.13 EPS. Regeneron Pharmaceuticals’s revenue for the quarter was up 23.0% on a year-over-year basis. research analysts expect that Regeneron Pharmaceuticals Inc will post 13.55 earnings per share for the current fiscal year.

A number of research analysts have recently commented on REGN shares. BMO Capital Markets set a $444.00 price target on Regeneron Pharmaceuticals and gave the company a “hold” rating in a report on Monday, November 27th. Citigroup lowered Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and lowered their price target for the company from $480.00 to $380.00 in a report on Friday, December 1st. Robert W. Baird raised Regeneron Pharmaceuticals from an “underperform” rating to a “neutral” rating in a report on Friday, November 3rd. Argus lowered their price target on Regeneron Pharmaceuticals from $540.00 to $470.00 and set a “buy” rating on the stock in a report on Thursday, December 28th. Finally, Zacks Investment Research lowered Regeneron Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, October 10th. Two investment analysts have rated the stock with a sell rating, fifteen have given a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $471.11.

COPYRIGHT VIOLATION NOTICE: This piece was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece on another website, it was stolen and reposted in violation of international copyright & trademark legislation. The correct version of this piece can be read at https://www.dispatchtribunal.com/2018/01/22/atria-investments-llc-has-726000-holdings-in-regeneron-pharmaceuticals-inc-regn.html.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals Inc (NASDAQ:REGN).

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply